Audrey R. Odom John, M.D., Ph.D.  odom_a@kids.wustl.edu

Assistant Professor of Pediatrics, Infectious Diseases
Infectious DiseasesPathobiologyMolecular Microbiology

phone: (314) 454-6050

Clinical Interests

As a subspecialist in pediatric infectious diseases, Dr. Odom cares for children with severe or prolonged infections, such as bone and joint infections, meningitis and sepsis. Dr. Odom also has expertise in evaluating and treating infections with unusual presentations, prolonged or recurrent fevers, as well as more unusual infections including atypical bacterial infections, viral infections, tick-borne illnesses, fungal infections, and tuberculosis. Dr. Odom also cares for patients with immunodeficiencies with associated infections.

Education

  • BS, summa cum laude, Duke University1996
  • PhD, Duke University School of Medicine2002
  • MD, Duke University School of Medicine2003

Training

  • Doctoral research: Duke University Medical Center, Advisor: John York PhD. Nuclear functions of an inositol polyphosphate kinase pathway1998 - 2002
  • Pediatric Residency (Special Alternative Pathway), University of Washington2003 - 2005
  • Fellowship research: University of Washington, Advisor: Wesley Van Voorhis MD PhD. Isoprenoid biosynthesis in the malaria parasite, Plasmodium falciparum2005 - 2008
  • Pediatric Infectious Diseases Fellowship, University of Washington2005 - 2008

Licensure and Board Certification

  • MO, Physician and Surgeon 2008
  • ABP, General Pediatrics, # 095581 2009
  • ABP Sub-board of Pediatric Infectious Diseases, # 1270 2011

Honors

  • Contributing member, Faculty of 1000 - Pres
  • Howard Hughes Medical Institute, Forum Fellows Grant1995
  • Phi Beta Kappa1996
  • Alpha Omega Alpha1998
  • American Cancer Society Institutional Research Grant Student Award1999
  • Harold M. Weintraub Graduate Student Award2001
  • Pediatric Infectious Diseases Society Fellowship Award2007
  • Scholar, WU Child Health Research Center of Excellence2008
  • Children's Discovery Institute, New Faculty Recruitment Award2009
  • Doris Duke Charitable Foundation Clinical Scientist Development Award2010
  • Mentor of the year, Washington University2010
  • Co-chair, Drug Discovery for Eukaryotic Pathogens and Parasites session, Keystone Symposium, Drug Discovery for Protozoan Parasites, Santa Fe, NM2012
  • Innovator award, St. Louis Academy of Sciences2012
  • Basil O'Connor Starter Scholar Award, March of Dimes2013
  • Election, Society for Pediatric Research2014
  • Grand Challenge winner and invited speaker, TEDxKC2015
  • Burroughs Wellcome Fund, Investigator in the Pathogenesis of Infectious Diseases (PATH)2016
  • Emerging Leader Award, Duke University School of Medicine alumni association2016
  • American Chemical Society Infectious Diseases, Young Investigator Award2016

Recent Publications view all (27)


Publication Co-Authors

  1. Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis. ACS Infect Dis. 2016. PMID:27676224 
  2. A novel FRET-based screen in high-throughput format to identify inhibitors of malarial and human glucose transporters. Antimicrob Agents Chemother. 2016. PMID:27736766 
  3. Whole genome sequencing to evaluate the resistance landscape following antimalarial treatment failure with fosmidomycin-clindamycin. J Infect Dis. 2016. PMID:27443612 
  4. Determinants of Anemia and Hemoglobin Concentration in Haitian School-Aged Children. Am J Trop Med Hyg. 2015;93(5):1092-8. PMCID:PMC4703262  PMID:26350448 
  5. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. Antimicrob Agents Chemother. 2015;59(10):6203-9. PMCID:PMC4576095  PMID:26248369 
  6. Cap-domain closure enables diverse substrate recognition by the C2-type haloacid dehalogenase-like sugar phosphatase Plasmodium falciparum HAD1. Acta Crystallogr D Biol Crystallogr. 2015;71(Pt 9):1824-34. PMCID:PMC4556313  PMID:26327372 
  7. Sweet Talk: Regulating Glucose Metabolism in Toxoplasma. Cell Host Microbe. 2015;18(2):142-3. PMID:26269950 
  8. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr). Antimicrob Agents Chemother. 2015. doi:10.1128/AAC.00602-15  PMID:26124156 
  9. Plasmodium IspD (2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target. ACS Infect Dis. 2015;1(4):157-167. PMCID:PMC4714788  PMID:26783558 
  10. Malaria parasites produce volatile mosquito attractants. MBio. 2015;6(2). doi:10.1128/mBio.00235-15  PMCID:PMC4453533  PMID:25805727 
  11. Isoprenoid metabolism in apicomplexan parasites. Curr Clin Microbiol Rep. 2014;1(3-4):37-50. doi:10.1007/s40588-014-0006-7  PMCID:PMC4399553  PMID:25893156 
  12. Isoprenoid biosynthesis in Plasmodium falciparum. Eukaryot Cell. 2014;13(11):1348-59. doi:10.1128/EC.00160-14  PMCID:PMC4248697  PMID:25217461 
  13. A sugar phosphatase regulates the methylerythritol phosphate (MEP) pathway in malaria parasites. Nat Commun. 2014;5:4467. doi:10.1038/ncomms5467  PMCID:PMC4112465  PMID:25058848 
  14. The triphenylethylenes, a novel class of antifungals. MBio. 2014;5(3):e01126-14. PMCID:PMC4010834  PMID:24781746 
  15. Isoprenoid biosynthesis inhibition disrupts Rab5 localization and food vacuolar integrity in Plasmodium falciparum. Eukaryot Cell. 2013;12(2):215-23. doi:10.1128/EC.00073-12  PMID:23223036 
  16. Structural studies and protein engineering of inositol phosphate multikinase. J Biol Chem. 2012;287(42):35360-9. doi:10.1074/jbc.M112.365031  PMCID:PMC3471723  PMID:22896696 
  17. Five questions about non-mevalonate isoprenoid biosynthesis. PLoS Pathog. 2011;7(12):e1002323. PMCID:PMC3245312  PMID:22216001 
  18. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry. 2011;50(17):3570-7. doi:10.1021/bi200113y  PMCID:PMC3082593  PMID:21438569 
  19. Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene. Mol Biochem Parasitol. 2010;170(2):108-11. doi:10.1016/j.molbiopara.2009.12.001  PMCID:PMC2814890  PMID:20018214 
  20. Molecular and biochemical characterization of two plant inositol polyphosphate 6-/3-/5-kinases. J Biol Chem. 2002;277(45):42711-8. doi:10.1074/jbc.M209112200  PMID:12226109 
  21. Characterization of the MFalpha pheromone of the human fungal pathogen cryptococcus neoformans. Mol Microbiol. 2000;38(5):1017-26. PMID:11123675 
  22. A role for nuclear inositol 1,4,5-trisphosphate kinase in transcriptional control. Science. 2000;287(5460):2026-9. PMID:10720331 
  23. A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science. 1999;285(5424):96-100. PMID:10390371 
  24. Nickel inhibits binding of alpha2-macroglobulin-methylamine to the low-density lipoprotein receptor-related protein/alpha2-macroglobulin receptor but not the alpha2-macroglobulin signaling receptor. Biochemistry. 1997;36(41):12395-9. doi:10.1021/bi970806k  PMID:9376342 
  25. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 1997;16(10):2576-89. doi:10.1093/emboj/16.10.2576  PMCID:PMC1169869  PMID:9184205 
  26. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother. 1997;41(1):156-61. PMCID:PMC163677  PMID:8980772 
  27. The effect of acrylamide and other sulfhydryl alkylators on the ability of dynein and kinesin to translocate microtubules in vitro. Toxicol Appl Pharmacol. 1995;133(1):73-81. doi:10.1006/taap.1995.1128  PMID:7597712 
Wash U School of Medicine
Children's Hospital St. Louis
Children's Discovery Institute
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130